-
2024-512126-29-00
5
2025-02-25
Generalized Myasthenia Gravis
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-507555-29-00
9
2024-08-16
LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2022-501354-10-01
5
2023-06-21
axial spondyloarthritis
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2025-522979-29-00
5
2026-04-30
Acute myeloid leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-522012-16-00
4
2026-03-13
Breast Cancer
-
2025-522701-38-00
6
2026-02-26
SUBRETINAL HYPERREFLECTIVE MATERIAL
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-522700-24-00
5
2026-01-13
CHRONIC OMALGIA
-
2025-520831-18-00
4
2025-12-12
Primary Sjogren’s Disease
-
2024-515201-26-00
4
2025-12-09
Small cell lung cancer (SCLC)
-
2024-519913-76-00
4
2025-12-09
PDL1-negative metastatic triple-negative breast cancer
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C